乐胖代购免代理版

{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:37:57Z","timestamp":1740123477059,"version":"3.37.3"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U24 CA224370"],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2023,12]]},"abstract":"Abstract<\/jats:title>DrugCentral, accessible at https:\/\/drugcentral.org<\/jats:ext-link>, is an open-access online drug information repository. It covers over 4950 drugs, incorporating structural, physicochemical, and pharmacological details to support drug discovery, development, and repositioning. With around 20,000 bioactivity data points, manual curation enhances information from several major digital sources. Approximately 724 mechanism-of-action (MoA) targets offer updated drug target insights. The platform captures clinical data: over 14,300 on- and off-label uses, 27,000 contraindications, and around 340,000 adverse drug events from pharmacovigilance reports. DrugCentral encompasses information from molecular structures to marketed formulations, providing a comprehensive pharmaceutical reference. Users can easily navigate basic drug information and key features, making DrugCentral a versatile, unique resource. Furthermore, we present a use-case example where we utilize experimentally determined data from DrugCentral to support drug repurposing. A minimum activity threshold t<\/jats:italic> should be considered against novel targets to repurpose a drug. Analyzing 1156 bioactivities for human MoA targets suggests a general threshold of 1\u00a0\u00b5M: t<\/jats:italic>\u2009=\u20096 when expressed as\u2009\u2212\u2009log[Activity(M)]). This applies to 87% of the drugs. Moreover, t<\/jats:italic> can be refined empirically based on water solubility (S): t<\/jats:italic>\u2009=\u20093 \u2212 logS, for logS\u2009<\u2009\u2212\u00a03. Alongside the drug repurposing classification scheme, which considers intellectual property rights, market exclusivity protections, and market accessibility, DrugCentral provides valuable data to prioritize candidates for drug repurposing programs efficiently.<\/jats:p>","DOI":"10.1007\/s10822-023-00529-x","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T13:50:52Z","timestamp":1694699452000},"page":"681-694","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploring DrugCentral: from molecular structures to clinical effects"],"prefix":"10.1007","volume":"37","author":[{"given":"Liliana","family":"Halip","sequence":"first","affiliation":[]},{"given":"Sorin","family":"Avram","sequence":"additional","affiliation":[]},{"given":"Ramona","family":"Curpan","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Borota","sequence":"additional","affiliation":[]},{"given":"Alina","family":"Bora","sequence":"additional","affiliation":[]},{"given":"Cristian","family":"Bologa","sequence":"additional","affiliation":[]},{"given":"Tudor I.","family":"Oprea","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"529_CR1","doi-asserted-by":"publisher","first-page":"D932","DOI":"10.1093\/nar\/gkw993","volume":"45","author":"O Ursu","year":"2016","unstructured":"Ursu O, Holmes J, Knockel J et al (2016) DrugCentral: online drug compendium. Nucleic Acids Res 45:D932\u2013D939","journal-title":"Nucleic Acids Res"},{"key":"529_CR2","doi-asserted-by":"publisher","first-page":"D963","DOI":"10.1093\/nar\/gky963","volume":"47","author":"O Ursu","year":"2019","unstructured":"Ursu O, Holmes J, Bologa CG et al (2019) DrugCentral 2018: an update. Nucleic Acids Res 47:D963\u2013D970","journal-title":"Nucleic Acids Res"},{"key":"529_CR3","doi-asserted-by":"publisher","first-page":"D1160","DOI":"10.1093\/nar\/gkaa997","volume":"49","author":"S Avram","year":"2021","unstructured":"Avram S, Bologa CG, Holmes J et al (2021) DrugCentral 2021 supports drug discovery and repositioning. Nucleic Acids Res 49:D1160\u2013D1169","journal-title":"Nucleic Acids Res"},{"key":"529_CR4","doi-asserted-by":"publisher","first-page":"D1276","DOI":"10.1093\/nar\/gkac1085","volume":"51","author":"S Avram","year":"2023","unstructured":"Avram S, Wilson TB, Curpan R et al (2023) DrugCentral 2023 extends human clinical data and integrates veterinary drugs. Nucleic Acids Res 51:D1276\u2013D1287","journal-title":"Nucleic Acids Res"},{"key":"529_CR5","unstructured":"FDA U.S. Food and Drug Administration. https:\/\/www.fda.gov\/. Accessed 31 Dec 2022"},{"key":"529_CR6","unstructured":"EMA European Medicines Agency. In: European medicines agency. https:\/\/www.ema.europa.eu\/en. Accessed 31 Dec 2022"},{"key":"529_CR7","unstructured":"Pharmaceuticals and Medical Devices Agency. https:\/\/www.pmda.go.jp\/english\/. Accessed 31 Dec 2022"},{"key":"529_CR8","unstructured":"World Health Organization\u2014international nonproprietary names programme and classification of medical products. https:\/\/www.who.int\/teams\/health-product-and-policy-standards\/inn\/. Accessed 22 Nov2022"},{"key":"529_CR9","unstructured":"AMA Finder. https:\/\/searchusan.ama-assn.org\/finder\/usan\/search\/*\/relevant\/1\/. Accessed 12 Jan 2023"},{"key":"529_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","volume":"23","author":"CA Lipinski","year":"1997","unstructured":"Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3\u201325","journal-title":"Adv Drug Deliv Rev"},{"key":"529_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1023\/A:1008130001697","volume":"14","author":"TI Oprea","year":"2000","unstructured":"Oprea TI (2000) Property distribution of drug-related chemical databases. J Comput Aided Mol Des 14:251\u2013264","journal-title":"J Comput Aided Mol Des"},{"key":"529_CR12","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1021\/cr00020a001","volume":"93","author":"AJ Leo","year":"1993","unstructured":"Leo AJ (1993) Calculating log Poct from structures. Chem Rev 93:1281\u20131306","journal-title":"Chem Rev"},{"key":"529_CR13","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1021\/jm000942e","volume":"43","author":"P Ertl","year":"2000","unstructured":"Ertl P, Rohde B, Selzer P (2000) Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 43:3714\u20133717","journal-title":"J Med Chem"},{"key":"529_CR14","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1016\/j.ejmech.2010.06.026","volume":"45","author":"F Milletti","year":"2010","unstructured":"Milletti F, Storchi L, Goracci L et al (2010) Extending pKa prediction accuracy: high-throughput pKa measurements to understand pKa modulation of new chemical series. Eur J Med Chem 45:4270\u20134279","journal-title":"Eur J Med Chem"},{"key":"529_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1208\/s12248-022-00687-0","volume":"24","author":"G Bocci","year":"2022","unstructured":"Bocci G, Oprea TI, Benet LZ (2022) State of the art and uses for the biopharmaceutics drug disposition classification system (BDDCS): new additions, revisions, and citation references. AAPS J 24:37","journal-title":"AAPS J"},{"key":"529_CR16","doi-asserted-by":"publisher","first-page":"D1214","DOI":"10.1093\/nar\/gkv1031","volume":"44","author":"J Hastings","year":"2016","unstructured":"Hastings J, Owen G, Dekker A et al (2016) ChEBI in 2016: improved services and an expanding collection of metabolites. Nucleic Acids Res 44:D1214\u2013D1219","journal-title":"Nucleic Acids Res"},{"key":"529_CR17","doi-asserted-by":"crossref","unstructured":"Nelson SJ (2009) Medical terminologies that work: the example of MeSH. In: 2009 10th International symposium on pervasive systems, algorithms, and networks. pp 380\u2013384","DOI":"10.1109\/I-SPAN.2009.84"},{"key":"529_CR18","unstructured":"U.S Food & Drug Administration Pharmacologic Class. https:\/\/www.fda.gov\/industry\/structured-product-labeling-resources\/pharmacologic-class. Accessed 11 Jan 2023"},{"key":"529_CR19","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.1021\/acs.jcim.0c00826","volume":"60","author":"S Avram","year":"2020","unstructured":"Avram S, Curpan R, Halip L et al (2020) Off-patent drug repositioning. J Chem Inf Model 60:5746\u20135753","journal-title":"J Chem Inf Model"},{"key":"529_CR20","unstructured":"Chemical Abstract Service (CAS). In: CAS. https:\/\/www.cas.org\/cas-data. Accessed 11 Jan 2023"},{"key":"529_CR21","unstructured":"KEGG: Kyoto encyclopedia of genes and genomes. https:\/\/www.genome.jp\/kegg\/. Accessed 10 Jan 2023"},{"key":"529_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13326-017-0161-x","volume":"8","author":"Y Lin","year":"2017","unstructured":"Lin Y, Mehta S, K\u00fc\u00e7\u00fck-McGinty H et al (2017) Drug target ontology to classify and integrate drug discovery data. J Biomed Semant 8:50","journal-title":"J Biomed Semant"},{"key":"529_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrd.2016.230","volume":"16","author":"R Santos","year":"2017","unstructured":"Santos R, Ursu O, Gaulton A et al (2017) A comprehensive map of molecular drug targets. Nat Rev Drug Discov 16:19\u201334","journal-title":"Nat Rev Drug Discov"},{"key":"529_CR24","doi-asserted-by":"publisher","first-page":"D930","DOI":"10.1093\/nar\/gky1075","volume":"47","author":"D Mendez","year":"2019","unstructured":"Mendez D, Gaulton A, Bento AP et al (2019) ChEMBL: towards direct deposition of bioassay data. Nucleic Acids Res 47:D930\u2013D940","journal-title":"Nucleic Acids Res"},{"key":"529_CR25","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/9783527619375.ch13b","volume-title":"Chemical biology","author":"M Olah","year":"2007","unstructured":"Olah M, Rad R, Ostopovici L et al (2007) WOMBAT and WOMBAT-PK: bioactivity databases for lead and drug discovery. Chemical biology. Wiley, Hoboken, pp 760\u2013786"},{"key":"529_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jbiotec.2005.03.022","volume":"119","author":"B Ganter","year":"2005","unstructured":"Ganter B, Tugendreich S, Pearson CI et al (2005) Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. J Biotechnol 119:219\u2013244","journal-title":"J Biotechnol"},{"key":"529_CR27","first-page":"D1006","volume":"48","author":"JF Armstrong","year":"2020","unstructured":"Armstrong JF, Faccenda E, Harding SD et al (2020) The IUPHAR\/BPS guide to pharmacology in 2020: extending immunopharmacology content and introducing the IUPHAR\/MMV guide to malaria pharmacology. Nucleic Acids Res 48:D1006\u2013D1021","journal-title":"Nucleic Acids Res"},{"key":"529_CR28","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/107385840000600408","volume":"6","author":"BL Roth","year":"2000","unstructured":"Roth BL, Lopez E, Patel S, Kroeze WK (2000) The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches? Neuroscientist 6:252\u2013262","journal-title":"Neuroscientist"},{"key":"529_CR29","doi-asserted-by":"publisher","first-page":"D480","DOI":"10.1093\/nar\/gkaa1100","volume":"49","author":"A Bateman","year":"2020","unstructured":"The UniProt Consortium, Bateman A, Martin M-J et al (2020) UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res 49:D480\u2013D489","journal-title":"Nucleic Acids Res"},{"key":"529_CR30","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.chembiol.2005.04.011","volume":"12","author":"ZA Knight","year":"2005","unstructured":"Knight ZA, Shokat KM (2005) Features of selective kinase inhibitors. Chem Biol 12:621\u2013637","journal-title":"Chem Biol"},{"key":"529_CR31","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s11095-018-2523-1","volume":"35","author":"S Avram","year":"2018","unstructured":"Avram S, Curpan R, Bora A et al (2018) Enhancing molecular promiscuity evaluation through assay profiles. Pharm Res 35:240","journal-title":"Pharm Res"},{"key":"529_CR32","first-page":"328","volume":"18","author":"O Ursu","year":"2019","unstructured":"Ursu O, Glick M, Oprea T (2019) Novel drug targets in 2018. Nat Rev Drug Discov 18:328","journal-title":"Nat Rev Drug Discov"},{"key":"529_CR33","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/d41573-020-00052-w","volume":"19","author":"S Avram","year":"2020","unstructured":"Avram S, Halip L, Curpan R, Oprea TI (2020) Novel drug targets in 2019. Nat Rev Drug Discov 19:300","journal-title":"Nat Rev Drug Discov"},{"key":"529_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/d41573-021-00057-z","volume":"20","author":"S Avram","year":"2021","unstructured":"Avram S, Halip L, Curpan R, Oprea TI (2021) Novel drug targets in 2020. Nat Rev Drug Discov 20:333","journal-title":"Nat Rev Drug Discov"},{"key":"529_CR35","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/d41573-022-00057-7","volume":"21","author":"S Avram","year":"2022","unstructured":"Avram S, Halip L, Curpan R, Oprea TI (2022) Novel drug targets in 2021. Nat Rev Drug Discov 21:328","journal-title":"Nat Rev Drug Discov"},{"key":"529_CR36","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/d41573-023-00068-y","volume":"22","author":"S Avram","year":"2023","unstructured":"Avram S, Halip L, Curpan R, Oprea TI (2023) Novel drug targets in 2022. Nat Rev Drug Discov 22:437","journal-title":"Nat Rev Drug Discov"},{"key":"529_CR37","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrd.2018.14","volume":"17","author":"TI Oprea","year":"2018","unstructured":"Oprea TI, Bologa CG, Brunak S et al (2018) Unexplored therapeutic opportunities in the human genome. Nat Rev Drug Discov 17:317\u2013332","journal-title":"Nat Rev Drug Discov"},{"key":"529_CR38","doi-asserted-by":"publisher","first-page":"D1334","DOI":"10.1093\/nar\/gkaa993","volume":"49","author":"TK Sheils","year":"2021","unstructured":"Sheils TK, Mathias SL, Kelleher KJ et al (2021) TCRD and Pharos 2021: mining the human proteome for disease biology. Nucleic Acids Res 49:D1334\u2013D1346","journal-title":"Nucleic Acids Res"},{"key":"529_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/cpbi.92","volume":"69","author":"T Sheils","year":"2020","unstructured":"Sheils T, Mathias SL, Siramshetty VB et al (2020) How to illuminate the druggable genome using pharos. Curr Protoc Bioinform 69:e92","journal-title":"Curr Protoc Bioinform"},{"key":"529_CR40","unstructured":"FDA Adverse Event Reporting System (FAERS). https:\/\/open.fda.gov\/data\/faers\/. Accessed 22 Nov 2022"},{"key":"529_CR41","unstructured":"OHDSI\u2014Observational health data sciences and informatics. https:\/\/www.ohdsi.org\/. Accessed 15 Aug 2018"},{"key":"529_CR42","first-page":"279","volume":"121","author":"K Donnelly","year":"2006","unstructured":"Donnelly K (2006) SNOMED-CT: the advanced terminology and coding system for eHealth. Stud Health Technol Inform 121:279\u2013290","journal-title":"Stud Health Technol Inform"},{"key":"529_CR43","doi-asserted-by":"publisher","first-page":"D267","DOI":"10.1093\/nar\/gkh061","volume":"32","author":"O Bodenreider","year":"2004","unstructured":"Bodenreider O (2004) The unified medical language system (UMLS): integrating biomedical terminology. Nucleic Acids Res 32:D267\u2013D270","journal-title":"Nucleic Acids Res"},{"key":"529_CR44","unstructured":"Disease Ontology\u2014Institute for genome sciences @ University of Maryland. https:\/\/disease-ontology.org\/. Accessed 12 Jan 2023"},{"key":"529_CR45","unstructured":"FDA\u2019s Global Substance Registration System. https:\/\/precision.fda.gov\/uniisearch. Accessed 22 Nov 2022"},{"key":"529_CR46","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA). https:\/\/www.meddra.org\/"},{"key":"529_CR47","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1198\/jasa.2011.ap10243","volume":"106","author":"L Huang","year":"2011","unstructured":"Huang L, Zalkikar J, Tiwari RC (2011) A likelihood ratio test based method for signal detection with application to FDA\u2019s drug safety data. J Am Stat Assoc 106:1230\u20131241","journal-title":"J Am Stat Assoc"},{"key":"529_CR48","unstructured":"National Library of Medicine (NLM)\u2019s DailyMed. https:\/\/dailymed.nlm.nih.gov\/dailymed\/. Accessed 23 Nov 2022"},{"key":"529_CR49","unstructured":"Orange Book: Approved drug products with therapeutic equivalence evaluations. Accessed 22 Nov 2022"},{"key":"529_CR50","unstructured":"National Institute of Health\u2019s Library of Integrated Network-Based Cellular Signatures (LINCS) Program. https:\/\/lincsproject.org\/"},{"key":"529_CR51","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian A, Narayan R, Corsello SM et al (2017) A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell 171:1437-1452.e17","journal-title":"Cell"},{"key":"529_CR52","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s42256-021-00335-w","volume":"3","author":"GB Kc","year":"2021","unstructured":"Kc GB, Bocci G, Verma S et al (2021) A machine learning platform to estimate anti-SARS-CoV-2 activities. Nat Mach Intell 3:527\u2013535","journal-title":"Nat Mach Intell"},{"key":"529_CR53","unstructured":"National Center for Advancing Translational Sciences\u2014OpenData portal: SARS-CoV-2 screening data. https:\/\/opendata.ncats.nih.gov\/covid19\/assays. Accessed 22 Nov 2022"},{"key":"529_CR54","doi-asserted-by":"publisher","unstructured":"Brimacombe KR, Zhao T, Eastman RT, et al. (2020) An OpenData portal to share COVID-19 drug repurposing data in real time. bioRxivorg. https:\/\/doi.org\/10.1101\/2020.06.04.135046","DOI":"10.1101\/2020.06.04.135046"},{"key":"529_CR55","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa F, Varoquaux G, Gramfort A et al (2011) Scikit-learn: machine learning in python. J Mach Learn Res 12:2825\u20132830","journal-title":"J Mach Learn Res"},{"key":"529_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.06.033","author":"AB Ingason","year":"2022","unstructured":"Ingason AB, Hreinsson JP, Agustsson AS et al (2022) Warfarin is associated with higher rates of upper but not lower gastrointestinal bleeding compared to direct oral anticoagulants: a population-based propensity-weighted cohort study. Clin Gastroenterol Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2022.06.033","journal-title":"Clin Gastroenterol Hepatol"},{"key":"529_CR57","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.coviro.2021.06.004","volume":"49","author":"J Sourimant","year":"2021","unstructured":"Sourimant J, Aggarwal M, Plemper RK (2021) Progress and pitfalls of a year of drug repurposing screens against COVID-19. Curr Opin Virol 49:183\u2013193","journal-title":"Curr Opin Virol"},{"key":"529_CR58","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/j.drudis.2022.03.003","volume":"27","author":"D Ghosh","year":"2022","unstructured":"Ghosh D, Sehgal K, Sodnar B et al (2022) Drug repurposing for stroke intervention. Drug Discov Today 27:1974\u20131982","journal-title":"Drug Discov Today"},{"key":"529_CR59","doi-asserted-by":"publisher","first-page":"5389","DOI":"10.2174\/0929867325666180530100332","volume":"26","author":"B Karaman","year":"2019","unstructured":"Karaman B, Sippl W (2019) Computational drug repurposing: current trends. Curr Med Chem 26:5389\u20135409","journal-title":"Curr Med Chem"},{"key":"529_CR60","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1042\/BST20200967","volume":"50","author":"JGL Mullins","year":"2022","unstructured":"Mullins JGL (2022) Drug repurposing in silico screening platforms. Biochem Soc Trans 50:747\u2013758","journal-title":"Biochem Soc Trans"},{"key":"529_CR61","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1021\/acsmedchemlett.0c00521","volume":"11","author":"MM Ghahremanpour","year":"2020","unstructured":"Ghahremanpour MM, Tirado-Rives J, Deshmukh M et al (2020) Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2. ACS Med Chem Lett 11:2526\u20132533","journal-title":"ACS Med Chem Lett"},{"key":"529_CR62","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jpha.2015.09.001","volume":"6","author":"DV Chaudhary","year":"2016","unstructured":"Chaudhary DV, Patel DP, Shah PA et al (2016) Determination of lercanidipine in human plasma by an improved UPLC-MS\/MS method for a bioequivalence study. J Pharm Anal 6:87\u201394","journal-title":"J Pharm Anal"},{"key":"529_CR63","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s10822-021-00430-5","volume":"35","author":"RA Lewis","year":"2021","unstructured":"Lewis RA (2021) Best practices for repurposing studies. J Comput Aided Mol Des 35:1189\u20131193","journal-title":"J Comput Aided Mol Des"},{"key":"529_CR64","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11095-004-9004-4","volume":"22","author":"C-Y Wu","year":"2005","unstructured":"Wu C-Y, Benet LZ (2005) Predicting drug disposition via application of BCS: transport\/absorption\/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11\u201323","journal-title":"Pharm Res"},{"key":"529_CR65","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/j.drudis.2019.09.021","volume":"24","author":"G Bocci","year":"2019","unstructured":"Bocci G, Benet LZ, Oprea TI (2019) Can BDDCS illuminate targets in drug design? Drug Discov Today 24:2299\u20132306","journal-title":"Drug Discov Today"}],"updated-by":[{"updated":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T00:00:00Z","timestamp":1701475200000},"DOI":"10.1007\/s10822-023-00545-x","type":"correction","source":"publisher","label":"Correction"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-023-00529-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-023-00529-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-023-00529-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T14:02:35Z","timestamp":1701525755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-023-00529-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":65,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["529"],"URL":"https:\/\/doi.org\/10.1007\/s10822-023-00529-x","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"type":"print","value":"0920-654X"},{"type":"electronic","value":"1573-4951"}],"subject":[],"published":{"date-parts":[[2023,9,14]]},"assertion":[{"value":"25 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10822-023-00545-x","URL":"https:\/\/doi.org\/10.1007\/s10822-023-00545-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.I.O. is a full-time employee of Expert Systems Inc. He was a full-time employee of AstraZeneca and Roivant Sciences. He served on the Scientific Advisory Board of ChemDiv Inc. and InSilico Medicine. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}